2.1
Vadadustat (Vafseo, MEDICE) is indicated for 'the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis'.
2 Information about vadadustat
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for vadadustat.
Price
2.3
The list prices of vadadustat are:
-
£148.59 per 28‑tablet pack of 150‑mg tablets (excluding VAT; company submission)
-
£520.08 per 98‑tablet pack of 150‑mg tablets (excluding VAT; company submission)
-
£297.19 per 28‑tablet pack of 300‑mg tablets (excluding VAT; company submission)
-
£1,040.16 per 98‑tablet pack of 300‑mg tablets (excluding VAT; company submission)
-
£445.78 per 28‑tablet pack of 450‑mg tablets (excluding VAT; company submission)
-
£1,560.23 per 98‑tablet pack of 450‑mg tablets (excluding VAT; company submission).
Annual treatment cost starts from £3,872.65 at the starting dosage of 300 mg per day (excluding VAT).
2.4
The company has a commercial arrangement. This makes vadadustat available to the NHS with a discount. The size of the discount is commercial in confidence.